A $6 million grant to Dr. Matthew Porteus and his team at Stanford University to develop an innovative stem cell-based gene correction therapy for chronic sinusitis in Cystic Fibrosis (CF) patients.  
 
CF is a common genetic disease that currently lacks a cure, causing patients to spend their lives managing symptoms. Despite significant advancements in CF therapies over the past two decades, effective treatments for serious sinus disease remain limited.

Improving quality of life

This therapy seeks to help CF patients with mutations unresponsive to current treatments or those who cannot tolerate existing options.

Sinus disease in CF does not affect mortality, but it reduces quality of life and can influence lung health.

The approach aims to permanently correct CFTR mutations and may offer longer‑lasting, transformative benefits beyond current therapies.

“The California Institute for Regenerative Medicine is proud to support this gene‑corrected sinus stem cell therapy for CF,” said Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM.

“We built a strong multidisciplinary team through the Stanford Center for Definitive and Curative Medicine,” said Dr. Porteus. “Partnering with CIRM to address this unmet need has been highly synergistic.”